Press Releases Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-02-07 pm EST			5-day change	1st Jan Change
32.60 ^USD	-3.01%		-17.30%	-21.60%

Feb. 04	Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.	DJ
Feb. 03	Wall Street: digesting the shock of the 'tariffs', Tesla falls 5%.	CF

Press Releases

Moderna reports record for UK clinical trials in 2023/24	Feb. 04	AQ
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union	Jan. 27	AQ
Moderna Announces Updates on Pandemic Influenza Program	Jan. 20	AQ
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference	Jan. 14	AQ
Moderna surprises the Street by predicting a bigger-than-expected sales drop	Jan. 13	AQ
Moderna to Present at Upcoming Conferences in December 2024	Nov. 26	AQ
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies	Nov. 21	AQ
Moderna : ASTMH 2024 (Zika Phase 2)	Nov. 15	PU
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year	Nov. 13	AQ
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older	Nov. 11	AQ
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 in Vivo CAR-M Therapy for Hepatocellular Carcinoma	Nov. 11	AQ
Moderna : SITC INT Phase 1 Trial Design	Nov. 08	PU
Moderna : SITC INT Phase 1 Trial Description	Nov. 08	PU
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma	Nov. 08	PR
IR Insights: Recapping our Third Quarter 2024 Earnings Report	Nov. 07	PU
Moderna : Reports Third Quarter 2024 Financial Results and Provides Business Updates Form 8 K	Nov. 07	PU
Moderna: Q3 Earnings Snapshot	Nov. 07	AQ
Carisma Therapeutics to Present New Data on Anti-GPC3 in Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024	Nov. 06	AQ
Moderna to Present at Upcoming Conferences in November 2024	Nov. 01	AQ
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 in Combination with KEYTRUDA After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer	24-10-29	AQ
Moderna Named a Top Employer by Science for Tenth Consecutive Year	24-10-25	AQ
Moderna : NORD Breakthrough Summit (PA patient experience)	24-10-19	PU
Moderna : NORD Breakthrough Summit (PA burden)	24-10-19	PU
Moderna : IDWeek 2024 (Norovirus)	24-10-18	PU
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm	24-10-08	BU

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am EDT

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm EST